BidaskClub Upgrades Coherus BioSciences (CHRS) to Buy

Leslie Hanson
May 15, 2018

Its up 0.09, from 1.07 in 2017Q3. ValuEngine downgraded Coherus BioSciences from a sell rating to a strong sell rating in a research note on Saturday, April 21st.

Tiaa Cref Inv Mngmt Ltd Liability Company stated it has 1.04 million shs or 0.01% of all its holdings. 2,819 are held by Tower Rech Cap Limited Co (Trc). Fmr Limited Liability Corporation owns 0.01% invested in Coherus BioSciences, Inc. L.P. reported 3.06 million shares in Charming Shoppes Inc equivalent to 0.26% of its long stock exposure. Citadel Advsrs Lc reported 1.77 million shares. Tekla Mgmt Ltd holds 90,000 shs or 0.03% of its capital. BlackRock Inc. raised its holdings in Coherus BioSciences by 4.2% during the first quarter. CHRS underperformed by 60.62% the S&P500. New York-based Morgan Stanley has invested 0% in Coherus BioSciences, Inc. Landscape Capital Management L.L.C. acquired a new stake in Coherus BioSciences in the fourth quarter valued at $116,000.

Coherus BioSciences (NASDAQ:CHRS) last issued its quarterly earnings data on Thursday, May 10th. Price T Rowe Associates Incorporated Md holds 919,202 shs or 0% of its capital. Legal & General Gru Public Limited Company reported 10,387 shs. Rock Springs Mgmt L P has 0.25% invested in Coherus BioSciences, Inc. The Switzerland-based Swiss State Bank has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Vanguard Group reported 0% stake.


NASDAQ CHRS traded up $1.25 during mid-day trading on Tuesday, hitting $16.20. The PT would indicate a potential upside of 31.34 % from the last stock close price of Coherus BioSciences (NASDAQ:CHRS). BidaskClub raised shares of Coherus BioSciences from a "sell" rating to a "hold" rating in a research report on Wednesday, February 28th. The positive are 100%. Coherus BioSciences has a twelve month low of $14.90 and a twelve month high of $16.65. The stock now has an average rating of "Buy" and an average price target of $29.33. Since March 9, 2018 according to StockzIntelligence Inc Coherus Biosciences has 2 analyst reports. On Friday, March 9 the firm earned "Buy" rating by Citigroup. Finally, Maxim Group restated a buy rating and issued a $15.00 target price (down previously from $20.00) on shares of Coherus BioSciences in a research note on Friday, March 9th. The stock had a trading volume of 33,041 shares, compared to its average volume of 524,415. The ratio improved due to Coherus BioSciences, Inc. positioning: 13 sold and 24 reduced.

The companyÂ's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonÂ-small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma.now it has negative earnings. The company has market cap of $1.01 billion. The companyÂ's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonÂ-small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma.now it has negative earnings. It now has negative earnings. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Ameritas Partners stated it has 0% in Coherus BioSciences, Inc. 43 active investment managers increased and started new holdings, while 37 reduced and sold holdings in Charming Shoppes Inc so the sentiment is positive.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER